Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

This phase 1, open-label, dose-escalation, multi-center study (NCT05477186) assessed the safety and immunogenicity of a booster dose of an mRNA COVID-19 vaccine (CV0501) encoding the SARS-CoV-2 Omicron BA.1 spike protein. Participants aged ≥ 18 years previously vaccinated with ≥ 2 doses of an mRNA C...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2408863
Hauptverfasser:	Essink, Brandon J., Shapiro, Craig, Isidro, Marie Grace Dawn, Bradley, Paul, Pragalos, Antoinette, Bloch, Mark, Santiaguel, Joel, Frias, Melchor Victor, Miyakis, Spiros, Alves de Mesquita, Margarida, Berrè, Stefano, Servais, Charlotte, Waugh, Natasha, Hoffmann, Claudia, Baba, Emna, Schönborn-Kellenberger, Oliver, Wolz, Olaf-Oliver, Koch, Sven D., Ganyani, Tapiwa, Boutet, Philippe, Mann, Philipp, Mueller, Stefan O., Ramanathan, Roshan, Gaudinski, Martin Robert, Vanhoutte, Nicolas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Neutralizing - blood Antibodies, Viral - blood booster clinical trial Coronavirus COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Female Humans Immunization, Secondary - methods immunogenicity Immunogenicity, Vaccine Lipids Liposomes Male Middle Aged mRNA vaccine mRNA Vaccines Nanoparticles - administration & dosage Nanovaccines safety SARS-CoV-2 - immunology SARS-CoV-2 variants Spike Glycoprotein, Coronavirus - immunology Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - adverse effects Vaccines, Synthetic - immunology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!